Getein Biotech Inc
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical … Read more
Getein Biotech Inc (603387) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.04 Billion CNY
Based on the latest financial reports, Getein Biotech Inc (603387) has total liabilities worth CN¥1.04 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Getein Biotech Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Getein Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Getein Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Getein Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Reway Group S.p.A.
F:IR0
|
Germany | €219.74 Million |
|
Zhejiang Netsun Co Ltd
SHE:002095
|
China | CN¥468.23 Million |
|
Chief Telecom Inc
TWO:6561
|
Taiwan | NT$3.78 Billion |
|
Altek Corp
TW:3059
|
Taiwan | NT$6.32 Billion |
|
Nok Airlines Public Company Limited
OTCGREY:NOKFF
|
USA | $23.77 Billion |
|
Kura Sushi USA Inc
NASDAQ:KRUS
|
USA | $214.31 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Getein Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Getein Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Getein Biotech Inc (2012–2024)
The table below shows the annual total liabilities of Getein Biotech Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥986.42 Million | -4.27% |
| 2023-12-31 | CN¥1.03 Billion | +1.73% |
| 2022-12-31 | CN¥1.01 Billion | +17.24% |
| 2021-12-31 | CN¥863.90 Million | +24.13% |
| 2020-12-31 | CN¥695.95 Million | +113.49% |
| 2019-12-31 | CN¥325.98 Million | +74.11% |
| 2018-12-31 | CN¥187.23 Million | +57.50% |
| 2017-12-31 | CN¥118.87 Million | +30.45% |
| 2016-12-31 | CN¥91.13 Million | +53.21% |
| 2015-12-31 | CN¥59.48 Million | +44.16% |
| 2014-12-31 | CN¥41.26 Million | -41.41% |
| 2013-12-31 | CN¥70.42 Million | +43.27% |
| 2012-12-31 | CN¥49.15 Million | -- |